Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CTIC $0.40 0.0520 +14.86%
THLD $1.01 0.1100 +12.22%
ARGS $5.22 0.3600 +7.41%
VRML $1.42 0.0900 +6.77%
ARRY $3.44 0.2000 +6.17%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

MNKD $0.75 -0.0440 -5.58%
KERX $4.32 -0.2500 -5.47%
MTP $4.18 -0.2200 -5.00%
SNSS $0.88 -0.0400 -4.35%
LBIO $8.20 -0.3700 -4.32%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

New Guide on DCIS Margins: Bigger Not Always Better

(Medscape Medical News) Aug 15, 2016 - Three major organizations jointly define what is adequate with regard to the margin width of surgically removed DCIS tissue and have a surprise about size.
read article (free registration required) 



OncoGenex Seeks Strategic Alternatives After Drug Study Fails

(Reuters) Aug 16, 2016 - OncoGenex Pharmaceuticals Inc said it was exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study in patients with advanced prostate cancer.
read article 



Chance Collaboration Yields an Advance in Cancer Treatment

(Wall Street Journal) Aug 15, 2016 - Researchers may have solved a puzzle about which patients will benefit from immunotherapy.
read article (paid subscription required) 



OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

(OncoGenex) Aug 16, 2016 - OncoGenex Pharmaceuticals, Inc. announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel.
read corporate press release 



New DCIS Consensus Guideline Could Curb Unnecessary Breast Surgery and Reduce Health System Costs

(Society of Surgical Oncology) Aug 15, 2016 - SSO, ASTRO and ASCO issue joint statement on margins for breast-conserving surgery with whole breast irradiation in ductal carcinoma in situ (DCIS).
read press release 



DTC Ads For Opdivo Face Further Backlash

(Medical Marketing and Media) Aug 15, 2016 - A pair of commentaries criticized Bristol-Myers Squibb's direct-to-consumer ads for Opdivo, its immuno-oncology drug, arguing that the ad's message is misleading.
read article 



In Battle Of Health Care Titans, Should Insurers Act Like Wal-Mart?

(NPR/Shots blog) Aug 11, 2016 - Evidence shows dominant insurers hold down hospital prices. Big insurers seeking to get bigger want to take that idea to the extreme. Hospitals and doctors object.
read article 



Few Docs Ready For Risk Under MACRA

(Modern Healthcare) Aug 13, 2016 - Hospital boardrooms are beginning to sound more like those on Wall Street, with talk of upside and downside risk, capitation and a hefty addition of new acronyms.
read article (free registration required) 



Medicare Changes Fiercely Resisted

(The Hill) Aug 12, 2016 - The Obama administration is hitting resistance from industry groups as it tries to change Medicare payments before leaving office.
read article 



Secrecy Shrouds Boards That Wield Immense Power Over Prescription Drug Coverage

(KHN Morning Briefing) Aug 15, 2016 - Pharmacy benefit managers release a list of drugs they're excluding for coverage for the year, which helps pressure drugmakers into keeping prices affordable. But the people on the board that makes those decisions are undisclosed, and critics are calling for increased transparency.
read article 



Opinion: Many Cancer Patients Must Face Bankruptcy—Or Die

(Newsweek) Aug 13, 2016 - Health care spending in the United States is like a runaway train. It seemingly can’t be slowed.
read article 



Weight Watchers And The American Cancer Society Launch Initiative To Support Holistic Health For Breast Cancer Survivors

(Yahoo! Finance) Aug 15, 2016 - Today, Weight Watchers International, Inc. (WTW) launched Project L.I.F.T. – Live Inspired, Fight Together – a new movement, in collaboration with the American Cancer Society, to inspire and guide breast cancer survivors with free resources focused on tackling the unexpected weight gain that can follow breast cancer treatment.
read article 



Germany: Prosecutors Probe 3 Deaths At Cancer Clinic

(FoxNews/Associated Press) Aug 12, 2016 - German prosecutors say they're investigating the operator of a clinic near the Dutch border that offers alternative cancer treatment on suspicion of negligent manslaughter and bodily harm after three people who were treated at the facility died.
read article 



Fraud Rounds: Grant Fakery Earns Practice Ban

(MedPage Today blog) Aug 12, 2016 - Cancer researcher struck from U.K. medical register after fabricating data in grant applications.
read article (free registration required) 



Why Doctors Want A Computerized Assistant For Cancer Care

(NPR/Shots blog) Aug 12, 2016 - There's more information on genetic mutations and in the scientific literature than cancer doctors can process easily. Smart, fast computers might be able to help.
read article 



CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma (PTCL)

(iCell Gene Therapeutics) Aug 11, 2016 - iCell Gene Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL).
read corporate press release 



CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries without Cost Sharing

(The Business Journal) Aug 15, 2016 - Exact Sciences Corp. announced that the Centers for Medicare and Medicaid Services (CMS) issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of Cologuard every three years without patient coinsurance, copayments or deductibles.
read article 



Bavarian Nordic Announces Drug Supply Agreement With Bristol-Myers Squibb For NSCLC Clinical Study

(Bavarian Nordic) Aug 15, 2016 - Bavarian Nordic A/S today announced the signature of a drug supply agreement with Bristol-Myers Squibb (BMS). Based on the agreement, BMS will supply OPDIVO® (nivolumab) to Bavarian Nordic for use in a clinical study.
read corporate press release 



Sun BioPharma Announces Completion of the Second Patient Cohort and Starts Recruitment of Third Cohort Patients in the Dose Escalation Phase 1 Study of SBP101 for Pancreatic Cancer

(Yahoo! Finance) Aug 15, 2016 - Sun BioPharma, Inc., a biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic diseases, today reported additional progress in the Phase 1 Study of the Company’s candidate SBP101 for pancreatic cancer.
read article 



BeyondSpring Announces First Patient Enrolled in China in a Global Phase 3 Trial of Plinabulin for Non-Small Cell Lung Cancer

(The Business Journal) Aug 15, 2016 - BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced today that the first patient in the global Phase 3 trial of its lead immuno-oncology asset Plinabulin, was enrolled in China on August 12, 2016 at the Shanghai Chest Hospital in Shanghai by Dr. Baohui Han, the principal investigator at this site.
read article 



AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma

(MarketWatch) Aug 15, 2016 - AVEO Oncology today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC).
read article 



Study Finds Hispanic Men In California Need More Screening For Colorectal Cancer

(UC Davis Health System) Aug 11, 2016 - Colorectal cancer incidence and mortality rates in California have decreased markedly for men and women in all major racial-ethnic groups since 1990, except for Hispanic men.
read press release 



Expanded Role of PARP Proteins Opens The Door To Explore New Therapeutic Targets In Cancer, Other Diseases

(UT Southwestern) Aug 15, 2016 - Using technology they developed, UT Southwestern Medical Center researchers have identified a previously unknown role of a certain class of proteins: as regulators of gene activity and RNA processing.
read press release 



‘Bursts’ of Chromosome Changes Fuel Breast Cancer Tumor Growth

(MD Anderson) Aug 15, 2016 - As with most cancers, triple-negative breast cancer (TNBC) cells have abnormal amounts of chromosomes or DNA copy number aberrations (CNAs) in their genomes.
read press release 



Mutations Tied to Outcomes in ER+ Metastatic Breast Cancer

(Medscape Medical News) Aug 12, 2016 - Prevalence of two mutations tripled when aromatase inhibitor treatment failed in the metastatic disease setting, and the mutations were associated with significantly shorter median overall survival.
read article (free registration required)